Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alberto J. Napuli is active.

Publication


Featured researches published by Alberto J. Napuli.


Nature Structural & Molecular Biology | 2010

Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.

Kayode K. Ojo; Eric T. Larson; Katelyn R. Keyloun; Lisa J. Castaneda; Amy E. DeRocher; Krishna K Inampudi; Jessica E. Kim; Tracy L. Arakaki; Ryan C. Murphy; Li Zhang; Alberto J. Napuli; Dustin J. Maly; Christophe L. M. J. Verlinde; Frederick S. Buckner; Marilyn Parsons; Wim G. J. Hol; Ethan A. Merritt; Wesley C. Van Voorhis

New drugs are needed to treat toxoplasmosis. Toxoplasma gondii calcium-dependent protein kinases (TgCDPKs) are attractive targets because they are absent in mammals. We show that TgCDPK1 is inhibited by low nanomolar levels of bumped kinase inhibitors (BKIs), compounds inactive against mammalian kinases. Cocrystal structures of TgCDPK1 with BKIs confirm that the structural basis for selectivity is due to the unique glycine gatekeeper residue in the ATP-binding site. We show that BKIs interfere with an early step in T. gondii infection of human cells in culture. Furthermore, we show that TgCDPK1 is the in vivo target of BKIs because T. gondii expressing a glycine to methionine gatekeeper mutant enzyme show significantly decreased sensitivity to BKIs. Thus, design of selective TgCDPK1 inhibitors with low host toxicity may be achievable.


PLOS ONE | 2013

Combining functional and structural genomics to sample the essential Burkholderia structome.

Loren Baugh; Larry A. Gallagher; Rapatbhorn Patrapuvich; Matthew C. Clifton; Anna S. Gardberg; Thomas E. Edwards; Brianna Armour; Darren W. Begley; Shellie H. Dieterich; David M. Dranow; Jan Abendroth; James W. Fairman; David Fox; Bart L. Staker; Isabelle Phan; Angela K. Gillespie; Ryan Choi; Steve Nakazawa-Hewitt; Mary Trang Nguyen; Alberto J. Napuli; Lynn K. Barrett; Garry W. Buchko; Robin Stacy; Peter J. Myler; Lance J. Stewart; Colin Manoil; Wesley C. Van Voorhis

Background The genus Burkholderia includes pathogenic gram-negative bacteria that cause melioidosis, glanders, and pulmonary infections of patients with cancer and cystic fibrosis. Drug resistance has made development of new antimicrobials critical. Many approaches to discovering new antimicrobials, such as structure-based drug design and whole cell phenotypic screens followed by lead refinement, require high-resolution structures of proteins essential to the parasite. Methodology/Principal Findings We experimentally identified 406 putative essential genes in B. thailandensis, a low-virulence species phylogenetically similar to B. pseudomallei, the causative agent of melioidosis, using saturation-level transposon mutagenesis and next-generation sequencing (Tn-seq). We selected 315 protein products of these genes based on structure-determination criteria, such as excluding very large and/or integral membrane proteins, and entered them into the Seattle Structural Genomics Center for Infection Disease (SSGCID) structure determination pipeline. To maximize structural coverage of these targets, we applied an “ortholog rescue” strategy for those producing insoluble or difficult to crystallize proteins, resulting in the addition of 387 orthologs (or paralogs) from seven other Burkholderia species into the SSGCID pipeline. This structural genomics approach yielded structures from 31 putative essential targets from B. thailandensis, and 25 orthologs from other Burkholderia species, yielding an overall structural coverage for 49 of the 406 essential gene families, with a total of 88 depositions into the Protein Data Bank. Of these, 25 proteins have properties of a potential antimicrobial drug target i.e., no close human homolog, part of an essential metabolic pathway, and a deep binding pocket. We describe the structures of several potential drug targets in detail. Conclusions/Significance This collection of structures, solubility and experimental essentiality data provides a resource for development of drugs against infections and diseases caused by Burkholderia. All expression clones and proteins created in this study are freely available by request.


Acta Crystallographica Section D-biological Crystallography | 2008

The plug-based nanovolume Microcapillary Protein Crystallization System (MPCS)

Cory J. Gerdts; Mark William Elliott; Scott Lovell; Mark B. Mixon; Alberto J. Napuli; Bart L. Staker; Peter Nollert; Lance J. Stewart

The Microcapillary Protein Crystallization System (MPCS) is a new protein-crystallization technology used to generate nanolitre-sized crystallization experiments for crystal screening and optimization. Using the MPCS, diffraction-ready crystals were grown in the plastic MPCS CrystalCard and were used to solve the structure of methionine-R-sulfoxide reductase.


Antimicrobial Agents and Chemotherapy | 2011

Selective Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Trypanosoma brucei Infection in Mice

Sayaka Shibata; J. Robert Gillespie; Angela Kelley; Alberto J. Napuli; Zhongsheng Zhang; Kuzma V. Kovzun; Ranae Pefley; Jocelyn Lam; Frank Zucker; Wesley C. Van Voorhis; Ethan A. Merritt; Wim G. J. Hol; Christophe L. M. J. Verlinde; Erkang Fan; Frederick S. Buckner

ABSTRACT Human African trypanosomiasis continues to be an important public health threat in extensive regions of sub-Saharan Africa. Treatment options for infected patients are unsatisfactory due to toxicity, difficult administration regimes, and poor efficacy of available drugs. The aminoacyl-tRNA synthetases were selected as attractive drug targets due to their essential roles in protein synthesis and cell survival. Comparative sequence analysis disclosed differences between the trypanosome and mammalian methionyl-tRNA synthetases (MetRSs) that suggested opportunities for selective inhibition using drug-like molecules. Experiments using RNA interference on the single MetRS of Trypanosoma brucei demonstrated that this gene product was essential for normal cell growth. Small molecules (diaryl diamines) similar to those shown to have potent activity on prokaryotic MetRS enzymes were synthesized and observed to have inhibitory activity on the T. brucei MetRS (50% inhibitory concentration, <50 nM) and on bloodstream forms of T. brucei cultures (50% effective concentration, as low as 4 nM). Twenty-one compounds had a close correlation between enzyme binding/inhibition and T. brucei growth inhibition, indicating that they were likely to be acting on the intended target. The compounds had minimal effects on mammalian cell growth at 20 μM, demonstrating a wide therapeutic index. The most potent compound was tested in the murine model of trypanosomiasis and demonstrated profound parasite suppression and delayed mortality. A homology model of the T. brucei MetRS based on other MetRS structures was used to model binding of the lead diaryl diamine compounds. Future studies will focus on improving the pharmacological properties of the MetRS inhibitors.


Journal of Biomolecular Screening | 2009

Buffer Optimization of Thermal Melt Assays of Plasmodium Proteins for Detection of Small-Molecule Ligands

Gregory J. Crowther; Alberto J. Napuli; Andrew P. Thomas; Diana J. Chung; Kuzma V. Kovzun; David J. Leibly; Lisa J. Castaneda; Janhavi Bhandari; Christopher J. Damman; Raymond Hui; Wim G. J. Hol; Frederick S. Buckner; Christophe L. M. J. Verlinde; Zhongsheng Zhang; Erkang Fan; Wesley C. Van Voorhis

In the past decade, thermal melt/thermal shift assays have become a common tool for identifying ligands and other factors that stabilize specific proteins. Increased stability is indicated by an increase in the proteins melting temperature (Tm). In optimizing the assays for subsequent screening of compound libraries, it is important to minimize the variability of Tm measurements so as to maximize the assays ability to detect potential ligands. The authors present an investigation of Tm variability in recombinant proteins from Plasmodium parasites. Ligands of Plasmodium proteins are particularly interesting as potential starting points for drugs for malaria, and new drugs are urgently needed. A single standard buffer (100 mM HEPES [pH 7.5], 150 mM NaCl) permitted estimation of Tm for 58 of 61 Plasmodium proteins tested. However, with several proteins, Tm could not be measured with a consistency suitable for high-throughput screening unless alternative protein-specific buffers were employed. The authors conclude that buffer optimization to minimize variability in Tm measurements increases the success of thermal melt screens involving proteins for which a standard buffer is suboptimal. (Journal of Biomolecular Screening 2009:700-707)


Acta Crystallographica Section F-structural Biology and Crystallization Communications | 2011

Immobilized metal-affinity chromatography protein-recovery screening is predictive of crystallographic structure success

Ryan Chang-Ho Choi; Angela Kelley; David J. Leibly; Stephen N. Hewitt; Alberto J. Napuli; Wesley C. Van Voorhis

An overview of the methods used for high-throughput cloning and protein-expression screening of SSGCID hexahistidine recombinant proteins is provided. It is demonstrated that screening for recombinant proteins that are highly recoverable from immobilized metal-affinity chromatography improves the likelihood that a protein will produce a structure.


Acta Crystallographica Section F-structural Biology and Crystallization Communications | 2011

High-throughput protein production and purification at the Seattle Structural Genomics Center for Infectious Disease

Cassie M. Bryan; Janhavi Bhandari; Alberto J. Napuli; David J. Leibly; Ryan Choi; Angela Kelley; Wesley C. Van Voorhis; Thomas E. Edwards; Lance J. Stewart

An overview of the standard SSGCID protein-purification protocol is given and success rates and cleavage alternatives are discussed.


Journal of Molecular Biology | 2010

Crystal Structures of Trypanosomal Histidyl-tRNA Synthetase Illuminate Differences between Eukaryotic and Prokaryotic Homologs ☆

Ethan A. Merritt; Tracy L. Arakaki; J. Robert Gillespie; Eric T. Larson; Angela Kelley; Natascha Mueller; Alberto J. Napuli; Jessica E. Kim; Li Zhang; Christophe L. M. J. Verlinde; Erkang Fan; Frank Zucker; Frederick S. Buckner; Wesley C. Van Voorhis; Wim G. J. Hol

Crystal structures of histidyl-tRNA synthetase (HisRS) from the eukaryotic parasites Trypanosoma brucei and Trypanosoma cruzi provide a first structural view of a eukaryotic form of this enzyme and reveal differences from bacterial homologs. HisRSs in general contain an extra domain inserted between conserved motifs 2 and 3 of the Class II aminoacyl-tRNA synthetase catalytic core. The current structures show that the three-dimensional topology of this domain is very different in bacterial and archaeal/eukaryotic forms of the enzyme. Comparison of apo and histidine-bound trypanosomal structures indicates substantial active-site rearrangement upon histidine binding but relatively little subsequent rearrangement after reaction of histidine with ATP to form the enzymes first reaction product, histidyladenylate. The specific residues involved in forming the binding pocket for the adenine moiety differ substantially both from the previously characterized binding site in bacterial structures and from the homologous residues in human HisRSs. The essentiality of the single HisRS gene in T. brucei is shown by a severe depression of parasite growth rate that results from even partial suppression of expression by RNA interference.


Journal of Molecular Biology | 2011

The Double-Length Tyrosyl-tRNA Synthetase from the Eukaryote Leishmania major Forms an Intrinsically Asymmetric Pseudo-Dimer.

Eric T. Larson; Jessica E. Kim; Lisa J. Castaneda; Alberto J. Napuli; Zhongsheng Zhang; Erkang Fan; Frank Zucker; Christophe L. M. J. Verlinde; Frederick S. Buckner; Wesley C. Van Voorhis; Wim G. J. Hol; Ethan A. Merritt

The single tyrosyl-tRNA synthetase (TyrRS) gene in trypanosomatid genomes codes for a protein that is twice the length of TyrRS from virtually all other organisms. Each half of the double-length TyrRS contains a catalytic domain and an anticodon-binding domain; however, the two halves retain only 17% sequence identity to each other. The structural and functional consequences of this duplication and divergence are unclear. TyrRS normally forms a homodimer in which the active site of one monomer pairs with the anticodon-binding domain from the other. However, crystal structures of Leishmania major TyrRS show that, instead, the two halves of a single molecule form a pseudo-dimer resembling the canonical TyrRS dimer. Curiously, the C-terminal copy of the catalytic domain has lost the catalytically important HIGH and KMSKS motifs characteristic of class I aminoacyl-tRNA synthetases. Thus, the pseudo-dimer contains only one functional active site (contributed by the N-terminal half) and only one functional anticodon recognition site (contributed by the C-terminal half). Despite biochemical evidence for negative cooperativity between the two active sites of the usual TyrRS homodimer, previous structures have captured a crystallographically-imposed symmetric state. As the L. major TyrRS pseudo-dimer is inherently asymmetric, conformational variations observed near the active site may be relevant to understanding how the state of a single active site is communicated across the dimer interface. Furthermore, substantial differences between trypanosomal TyrRS and human homologs are promising for the design of inhibitors that selectively target the parasite enzyme.


Current Topics in Medicinal Chemistry | 2009

Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium.

Christophe L. M. J. Verlinde; Erkang Fan; Sayaka Shibata; Zhongsheng Zhang; Zhihua Sun; Wei Deng; Jennifer M. Ross; Jessica E. Kim; Liren Xiao; Tracy L. Arakaki; Jürgen Bosch; Jonathan M. Caruthers; Eric T. Larson; Isolde LeTrong; Alberto J. Napuli; Angela Kelley; Natasha Mueller; Frank Zucker; Wesley C. Van Voorhis; Frederick S. Buckner; Ethan A. Merritt; Wim G. J. Hol

The history of fragment-based drug discovery, with an emphasis on crystallographic methods, is sketched, illuminating various contributions, including our own, which preceded the industrial development of the method. Subsequently, the creation of the BMSC fragment cocktails library is described. The BMSC collection currently comprises 68 cocktails of 10 compounds that are shape-wise diverse. The utility of these cocktails for initiating lead discovery in structure-based drug design has been explored by soaking numerous protein crystals obtained by our MSGPP (Medical Structural Genomics of Pathogenic Protozoa) consortium. Details of the fragment selection and cocktail design procedures, as well as examples of the successes obtained are given. The BMSC Fragment Cocktail recipes are available free of charge and are in use in over 20 academic labs.

Collaboration


Dive into the Alberto J. Napuli's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wim G. J. Hol

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Erkang Fan

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Frank Zucker

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Angela Kelley

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Eric T. Larson

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge